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Cilnidipine, a dual L-/N-type calcium channel blocker, dilates
both efferent and afferent arterioles and is renoprotective.
Our multi-center, open-labeled, and randomized trial
compared the antiproteinuric effect of cilnidipine with that
of amlodipine in hypertensive patients with kidney disease.
A group of 339 patients, already receiving renin–angiotensin
system inhibitor treatment, were randomly assigned to
cilnidipine or amlodipine. The primary endpoint was a
decrease in the urinary protein to creatinine ratio. After
1-year of treatment, systolic and diastolic blood pressures
were significantly reduced in both groups which did not
differ between them. The urinary protein to creatinine ratio
significantly decreased in the cilnidipine compared to the
amlodipine group. Cilnidipine exerted a greater
antiproteinuric effect than amlodipine even in the subgroup
whose blood pressure fell below the target level. This study
suggests that cilnidipine is superior to amlodipine in
preventing the progression of proteinuria in hypertensive
patients when coupled with a renin–angiotensin system
inhibitor.
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Based on the accumulating data from a large number of
clinical mega-trials,1–5 it has been established that an
inhibitor of the renin–angiotensin system (RAS), such as an
angiotensin-converting enzyme (ACE) inhibitor and an
angiotensin II type 1 receptor blocker (ARB), has an apparent
renoprotective effect. Although the guidelines for the
management of hypertension6–8 recommend that blood
pressure (BP) should be strictly controlled in hypertensive
patients with kidney disease, adequate BP levels are seldom
achieved with only one RAS inhibitor. Actually, combination of
two to three antihypertensive drugs is required to decrease BP
to target levels, especially in patients with kidney disease.9 One
of the main candidates for a combination with an RAS inhibitor
is a dihydropyridine-type calcium channel blocker (CCB),
because it reduces BP even in patients who are sometimes
considered relatively resistant to antihypertensive drugs.10
However, evidence for the renoprotective effect of
dihydropyridine CCBs is inconsistent. For example, ramipril
had a greater renoprotective effect compared with amlodi-
pine in the African American Study of Kidney Disease and
Hypertension (AASK) study.4 Moreover, the risk of a
doubling of the serum creatinine (Cr) was similar between
amlodipine and placebo groups in the Irbesartan Diabetic
Nephropathy Trial (IDNT).11 In a recent meta-analysis, the
mean change in urinary protein was approximately þ 2% for
dihydropyridine CCBs.12 On the other hand, the antiprotei-
nuric effect of cilnidipine has been shown in several types of
hypertensive animal models13,14 and hypertensive patients
with kidney disease.15,16 The addition of a dihydropyridine
CCB to treatment with an RAS inhibitor is also associated
with inconsistent renal effects. The Blood-pressure Control
for Renoprotection in Patients with Non-diabetic Chronic
Renal Disease Trial (REIN-2) group showed that the addition
of felodipine was not of further renal benefit in patients with
non-diabetic proteinuric nephropathies and background of
ramipril therapy.17 On the other hand, cilnidipine further
reduced urinary albumin in patients with type II diabetic
nephropathy under treatment with valsartan.18
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This inconsistency may be due to the different specificity
for calcium channels of each dihydropyridine CCB;19 there
are several variants of calcium channels, such as L, N, T, P/Q,
and R.20,21 Actually, cilnidipine, an L-/N-type dihydro-
pyridine CCB, was shown to suppress renal injury in
hypertensive animals and humans13–16 but amlodipine4,11
and felodipine,17 an L-type CCBs, were not. Cilnidipine had a
greater renoprotective effect than amlodipine in rat14 and
small-size clinical studies.16 The blockade of N-type calcium
channels is able to inhibit renal sympathetic nerve activity14
and the resulting efferent arteriolar vasodilation protected the
glomeruli through the attenuation of glomerular hyperten-
sion.13 However, because L-type calcium channels do not
express in glomerular efferent arterioles,22 the renoprotective
effects of an L-type CCB are expected to be lower than those
of an L-/N-type CCB. There is still a lack of clinical trials
comparing the renoprotective effects of an L-/N-type and L-
type CCBs added to treatment with an RAS inhibitor, which
is frequently prescribed for hypertensive disease in clinical
practice. Thus, we compared the antiproteinuric effects of
cilnidipine with those of amlodipine in hypertensive patients




Three hundred and fifty subjects were enrolled for this study
and of them 11 were excluded based on the selection criteria
(Figure 1). Thus, 339 subjects (these were 90.2% of required
sample size with our estimation) were randomly allocated to
the cilnidipine group (n¼ 179) or amlodipine group
(n¼ 160). The baseline characteristics of the subjects in the
two groups are shown in Table 1 and baseline medication is
shown in Table 2. There were no significant differences
between the two groups. The final dose was
11.575.6 mg day1 in the cilnidipine group and
5.372.4 mg day1 in the amlodipine group. Twenty subjects
from the cilnidipine group and 17 from the amlodipine
group were added antihypertensive drugs other than a CCB
or an RAS inhibitor during the treatment (cilnidipine group:
diuretic n¼ 12, a-blocker n¼ 5, b-blocker n¼ 5; amlodipine
group: diuretic n¼ 14, a-blocker n¼ 4, b-blocker n¼ 1).
During treatment, 32 subjects from the cilnidipine group
(adverse reaction: n¼ 9, cardiovascular event: n¼ 1, death:
n¼ 2, lost to follow-up: n¼ 20 (discontinuation: n¼ 13,
moving away: n¼ 4, protocol violation: n¼ 3)) and 30
subjects from the amlodipine group (adverse reaction:
n¼ 13, cardiovascular event: n¼ 4, death: n¼ 3, lost to
follow-up: n¼ 10 (discontinuation: n¼ 8, moving away:
n¼ 2)) withdrew from the study.
Changes in BP and heart rate
Systolic BP was slightly but significantly (Po0.05) greater at
2 months of treatment in the amlodipine group than in the
cilnidipine group but did not differ at the other time points
350 assessed for eligibility
339 randomized
11 excluded as ineligible
147 completed study  130 completed study
179 cilnidipine 160 amlodipine 
32 discontinued study drug
9  adverse reaction
1  cardiovascular events
2  died
20  lost to follow-up
30 discontinued study drug
13  adverse reaction
4  cardiovascular events
3  died
10  lost to follow-up
Figure 1 | Flow of participants throughout the study.
Table 1 | Baseline characteristics
Variable Cilnidipine Amlodipine P-value
n 179 160
Age (years) 59.9713.3 59.3712.9 NS
Sex (male/female) 121/58 93/67 NS
Causative disease
Diabetic nephropathy 70 59






Systolic BP (mm Hg) 152.4714.8 152.4714.8 NS
Diastolic BP (mm Hg) 86.979.6 88.079.4 NS
Heart rates (beats per min) 76712 74710 NS














Diabetes mellitus 81 (45%) 67 (42%) NS
Cerebrovascular disease 11 (6%) 7 (4%) NS
Ischemic heart disease 9 (5%) 9 (6%) NS
BP, blood pressure, Cr, creatinine, HDL, high-density lipoprotein; NS, not significant.
g
Table 2 | Baseline medication
Medication Cilnidipine Amlodipine P-value
RAS inhibitor
ARB 114 98
NSACE inhibitor 41 45
ARB+ACE inhibitor 24 17
Diuretics 45 45 NS
b-Blocker 16 17 NS
a-Blocker 17 16 NS
Central sympatholytic agent 1 1 NS
ACE, angiotensin-converting enzyme; ARB, angiotensin II type 1 blocker; NS, not
significant; RAS, renin-angiotensin system.
g
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(Figure 2). Diastolic BP did not differ between the two
groups during the treatment. In the last month of treatment,
systolic (cilnidipine; 133.1715.6 mm Hg, amlodipine;
134.5716.6 mm Hg, NS) and diastolic (75.678.7 vs
77.979.4 mm Hg, NS) BP did not differ either. Subjects
with a BPo140/90 mm Hg accounted for 69.3 and 62.3% in
the cilnidipine and amlodipine groups (NS), respectively.
Subjects with a BP o130/85 mm Hg accounted for 36.9 and
37.7% (NS), respectively; BP level of this subgroup was also
similar between cilnidipine and amlodipine groups (systolic
BP: 120.576.8 vs 118.976.5 mm Hg, diastolic BP: 71.377.7
vs 73.276.1 mm Hg, NS, respectively). Heart rate did not
differ either (cilnidipine; 73.9711.8 beats per min, amlodi-
pine; 73.6711.7 beats per min, NS).
Changes in urinary protein/Cr ratio
In the cilnidipine group, the urinary protein/Cr ratio was
significantly lower in the last month of the study than in the
amlodipine group (1308.67121.2 vs 1881.17188.8 mg g1:
s.e.m., Po0.05) (Figure 3). When the percent change from
baseline was calculated, it was significantly lower in the
cilnidipine group at 3 months of treatment or later. After 12
months of treatment, the urinary protein/Cr ratio had
decreased in the cilnidipine group (14.475.6%: s.e.m.)
but not in the amlodipine group (þ 13.977.7%: s.e.m.),
showing a significant (Po0.01) difference between the two
groups. Even in subgroups with different baseline, urinary
protein/Cr ratio, age, sex, or BP after the 12 months of
treatment, cilnidipine significantly suppressed the urinary
protein/Cr ratio compared with amlodipine (Figure 4). In a
subgroup with primary renal disease, cilnidipine was also
more antiproteinuric than amlodipine. In a subgroup with
diabetic nephropathy, although the percent changes in
urinary protein/Cr ratio did not differ between the two
groups (Figure 4), its absolute value was lower in the
cilnidipine group than in the amlodipine group
(1160.57171.6 vs 2405.07447.1 mg g1: s.e.m., Po0.05)
after 1 year of treatment, while the baseline urinary protein/
Cr ratio did not differ (2243.37330.4 vs 2137.57
268.3 mg g1: s.e.m., NS). However, in the subgroup with


























Figure 2 | Changes in systolic and diastolic BP. BP was almost
the same in the cilnidipine (closed circles) and the amlodipine
(open circles) groups except for a slight difference in systolic BP at
one point. *Po0.05, cilnidipine vs amlodipine groups.
Amlodipine 160 147 142 137 130











































Figure 3 | Changes in urinary protein/Cr ratio during the treatment period. Results are expressed as the mean7s.e.m. The urinary
protein/Cr ratio was suppressed in the cilnidipine group but not in the amlodipine group. *Po0.05, wPo0.01, cilnidipine vs amlodipine groups.
Subgroup n Changes in urinary protein P-value
Baseline urinary protein/Cr ratio
201







BP after 12-month treatment
<130/85 mm Hg 123
207
Diabetic nephropathy 129
Primary renal disease 118
Hypertensive nephrosclerosis 60













Figure 4 | Changes in urinary protein/Cr ratio in subgroups
with different baseline urinary protein/Cr ratio, age, sex, BP
after 12 months of treatment, or etiology of kidney disease.
Results are expressed as the mean7s.e.m. The antiproteinuric effect
was superior in the cilnidipine group compared with the amlodipine
group even in the different subgroups.
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not different between cilnidipine and amlodipine, probably
due to the small number of subjects (n¼ 60, totally).
Changes in serum Cr
The serum Cr was slightly increased in both groups, but after
1 year of treatment, the level was similar in the two groups
(1.3770.72 vs 1.4570.83 mg dl1).
Cardiovascular events and death
The occurrence of cardiovascular disease was two times
greater in the amlodipine group but the difference between
the two groups was not statistically significant (Table 3).
There was no case of cardiovascular death in the cilnidipine
group, while two subjects died in the amlodipine group
(sudden death and rupture of aortic aneurysm), but the
difference was not significant. The all cause mortality rate did
not significantly differ.
Adverse reactions
Adverse reactions were observed in 20 subjects of the
cilnidipine group and in 19 patients of the amlodipine
group (Table 4). About half of the adverse reactions in each
group (cilnidipine n¼ 10, amlodipine n¼ 10) were consid-
ered to relate to the study drugs. Severe adverse reactions
were observed in two subjects treated with cilnidipine
(exacerbation of renal failure and metastatic lung cancer)
and in four treated with amlodipine (general malaise, pleural
effusion, lung cancer, and carcinomatous peritonitis).
DISCUSSION
In this study, we firstly demonstrated that cilnidipine was
more beneficial than amlodipine as additional medication for
hypertensive patients who had kidney disease associated with
significant proteinuria (urinary protein/Cr ratio
X300 mg g1) and who were under treatment with an RAS
inhibitor. Our results further confirm those of previous
reports showing that cilnidipine had greater antiproteinuric
effects than amlodipine,14,16 and those of a study showing
that the combination therapy with cilnidipine and an ARB
ameliorated urinary albumin excretion more potently than
ARB monotherapy.18 In this study, moreover, cilnidipine was
more beneficial than amlodipine even under treatment of an
RAS inhibitor. As a dihydropyridine CCB is frequently
prescribed as secondary choice for patients with hypertensive
disease treated with an RAS inhibitor, the present results
should have an impact on the practical management of
hypertension associated with kidney disease; it is suggested
that cilnidipine, a dual L-/N-type CCB, rather than an L-type
CCB should be recommended to be ‘second agents’ in
hypertensive patients with significant proteinuria under
treatment with an RAS inhibitor.
In addition to RAS inhibition, strict BP control is
considered to play an important role in preventing the
progression of kidney disease.6–8 In this study, although
systolic and diastolic BPs did not differ as a whole, slight
lower systolic BP levels were observed in cilnidipine group at
2 month of the treatment. However, this insubstantial
difference of systolic BP for the short-time period may not
affect urinary protein. Also, in the previous report,23 24 h
ambulatory BP measurement showed no significant differ-
ence in the reduction in any of the BP parameters between
cilnidipine and amlodipine, associated with similar decrease
in office BP. In this study, required BP goal was not attended
as a whole. However, even in subjects whose BP was
controlled at o130/85 mm Hg, the antiproteinuric effect of
cilnidipine was greater compared with that of amlodipine
(Figure 4) despite the comparable BP reduction in both
groups, suggesting that the beneficial effect of cilnidipine may
be beyond its BP lowering effect. Therefore, even if the target
BP is achieved, the choice of an appropriate secondary
dihydropyridine CCB might be critical for hypertensive
patients with kidney disease under treatment with an RAS
inhibitor.
The greater antiproteinuric effect attained with cilnidipine
compared with amlodipine may be due to the N-type
calcium channel blockade achieved with cilnidipine, but not
with amlodipine, and the resultant sympathetic nerve
inhibition.14 Supporting this hypothesis, non-hypotensive
doses of moxonidine, an agent that reduces sympathetic
nerve activity, could ameliorate not only albuminuria but
also structural damage in subtotally nephrectomized rats,24
suggesting a potential role of the increased sympathetic nerve
Table 3 | Cardiovascular events and death
Cilnidipine Amlodipine
Cardiovascular disease 1 3
Angina pectoris 1 0
Myocardial infarction 0 1
Abdominal aortic rupture 0 1
Sudden death 0 1
Stroke 2 4
Cerebral infarction 2 3
Transient ischemic attack 0 1
All cause mortality 2 3
Cardiovascular death 0 2
Non-cardiovascular death 2 1





Hot flushes 0 1
Headache 0 1
Malaise, fatigue 1 1
Skin reaction 2 1
Abnormal laboratory data 6 0
Worsening of liver function 3 1
Worsening of kidney function 2 1
Others 9 12
Total number of patientsa 20 19
aFive patients with cilnidipine and one patient with amlodipine had two or more
adverse reactions.
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activity in progression of renal failure. There is a consistent
intimate relationship between the sympathetic nervous
system and urinary protein excretion in patients with chronic
kidney disease.25 For example, moxonidine reduced urinary
albumin in patients with essential hypertension.26 A number
of relatively small clinical studies have suggested that non-
dihydropyridine CCBs, which attenuated sympathetic nerve
activity, reduce urinary protein more markedly than
dihydropyridine CCBs, which do not exert a sympatho-
inhibitory effect, although both types of CCBs similarly
decrease BP.27,28 Accordingly, cilnidipine, a dual L-/N-type
CCB, has been reported to have a greater renoprotective
effect than amlodipine, an L-type CCB,14,16 which is
compatible with the result of this study. These findings are
supported by experimental studies indicating that cilnidi-
pine-induced N-type calcium channel blockade inhibits renal
sympathetic nerve activity,14 inducing a reduction of
glomerular hypertension through a vasodilation of efferent
arterioles,13 but that an L-type CCB does not effectively
reduce glomerular hypertension because of the absence of L-
type calcium channels in the efferent arterioles.22 Taken
together, these results strongly support the hypothesis that
the antiproteinuric effect of cilnidipine might be account for
the inhibition of sympathetic nerve activity through the
blockade of N-type calcium channels in chronic kidney
disease patients with the increased sympathetic activity.25,26
On the other hand, an L-type CCB may rather cause
sympathoactivation through a direct vasodilator effect.
Several clinical studies demonstrate that proteinuria is a
predictor of subsequent progression of kidney disease; for
example, in multivariate analysis of data from the AASK
study,29 baseline proteinuria correlated to decline of glomer-
ular filtration ratio independently. Importantly, proteinuria
has been recently recognized to be one of cardiovascular risk
factors. In the Framingham cohort, proteinuria showed a
three-fold increase of the mortality rate and was strongly
associated with other risk factors for cardiovascular disease.30
In a sub-analysis in the Systolic Hypertension in Europe
(Syst-Eur) trial,31 proteinuria was a significant predictor of
total mortality and all cardiovascular end points. Experi-
mental and clinical data converge to indicate that, in chronic
kidney disease, proteinuria reduction protects against renal
and cardiovascular failure.32 Fosinopril, which decreased
urinary albumin excretion, exhibited much greater reduction
of cardiovascular events during the 4-year follow-up than
calculated reduction using Framingham risk score, but
pravastatin, which did not affect urinary albumin, inhibited
cardiovascular events comparably to calculated reduction.33
Thus, antiproteinuric antihypertensive drugs are considered
to be more beneficial regarding the cardiovascular as well as
renal outcome in patients with kidney disease.
In this study, 24-h urine collection could not be carried
out, because it may be too inconvenient and cumbersome for
outpatients to give their cooperation to this study. Although
24 h urine collection is a gold standard that is suggested to be
a best practice,34 several investigators demonstrated that
urinary protein/Cr ratio in spot urine collection is well
correlated with daily urinary protein excretion.35–38 Actually,
systematic review by Price et al.39 suggested that the protein/
Cr ratio on a random urine specimen could be useful in
clinical practice. Also, the Work Group of the Kidney Disease
Outcomes Quality Initiative of the National Kidney Founda-
tion recommended first morning urine collection or random
spot urine collection to monitor proteinuria in patients with
established kidney disease.40 Actually, in clinical practice, 24 h
urine collection cannot be often accepted by patients with
mild to moderate kidney disease. Therefore, urinary protein/
Cr ratio from spot urine collection may be a parameter to
meet clinical practice, although there are some limitations in
spot urine collection.
Sample size and period of treatment are an additional
limitation of our study. Although the cardiovascular risks of
patients were mild to moderate, the number of patients was
relatively small (n¼ 339, totally) and this study was short
(1 year). Thus, cardiovascular events were too rare and the
changes in serum Cr were too slight to sufficiently evaluate
the influence of cilnidipine. Actually, the occurrence of
cardiovascular events and death in the cilnidipine group was
approximately half that of the amlodipine group, but the
difference was not statistically significant. Also, the changes in
serum Cr were not significantly different between the two
groups. Small sample size, moreover, causes a limitation of
subgroup analysis such as diabetic nephropathy and hyper-
tensive glomerulosclerosis (Figure 4). In addition, diagnosis
of cardiovascular event depended on judgment of individual
investigators, which was also a limitation on evaluation of
cardiovascular events in this study.
In conclusion, the addition of cilnidipine rather than
amlodipine ameliorated urinary protein excretion in hyper-
tensive patients with kidney disease who were already under
treatment with an RAS inhibitor. Therefore, combination
therapy with cilnidipine and an RAS inhibitor may be
recommended for these patients.
MATERIALS AND METHODS
Participants
This study was a multicenter, open-labeled, randomized trial
conducted in 35 hospitals (Appendix) in Japan from June 2002 to
July 2006. This study was approved by the Institutional Review
Board of The University of Tokyo Clinical Research Center and by
the review board of all the other hospitals, and it was undertaken in
accordance with the Declaration of Helsinki Principles. Written
informed consent was obtained from all subjects. The enrollment
criteria of the subjects included (1) urinary protein/Cr ratio
X300 mg g1 (average of two consecutive measurements during a
4-week period before the treatment), (2) serum Crp3.0 mg dl1, (3)
systolic and diastolic BPX130/85 mm Hg, and (4) treatment with an
ARB or an ACE inhibitor during 2–3 months or more before the
administration of cilnidipine or amlodipine. The exclusion criteria
were (1) age younger than 20 years or older than 80 years; (2)
hypertensive emergency; (3) severe heart failure, severe arrhythmia,
angina, and myocardial infarction within 6 months of the start of
the trial; (4) stroke within 6 months of the start of the trial; (5)
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severe diabetes mellitus, which required hospitalization because of
extremely high plasma glucose or complications such as diabetic
ketoacidosis; (6) pregnancy; and (7) history of severe side effects of a
CCB, an ARB or an ACE inhibitor. Required sample size was
estimated as 376 that significant difference could be detected when
the difference of both groups was 10% (statistical power: 80%, two-
sided level of significance: 5%) considering the previous report.15
Interventions
The subjects were randomly allocated to two groups, cilnidipine
(5–20 mg daily) or amlodipine (2.5–7.5 mg daily) in combination
with an ARB or an ACE inhibitor. Randomization was done
according to the assignment in sealed envelops for each subject to
indicate the grouping of subjects, which were send to investigators.
The monitoring investigator (KA), who did not treat study subjects
and did not know the profile of the subjects before the start of trial,
monitored randomization in order of the entry of the subjects in
each institute. The dose of an ARB or an ACE inhibitor was not
changed during the treatment period. The target BP was o130/
85 mm Hg. BP measurement was carried out according to the
Japanese Society of Hypertension Guidelines for Management of
Hypertension.8 If cilnidipine or amlodipine plus an RAS inhibitor
failed to reduce BP to the target level, a third drug (other than an
RAS inhibitor or a CCB) was added.
Outcome measures
The primary end point was changes in the urinary protein/Cr ratio
from the pretreatment period to 1, 3, 6, and 12 months of treatment.
Urinary protein was measured by Pyrogallol Red method. At each
time point, treatment compliance was checked at the outpatient
clinic. The key secondary outcomes were cardiovascular events,
which depended on judgment of individual investigators, and death.
In addition, urinary electrolytes, serum Cr, blood biochemistry,
blood cells counts, electrocardiography, and chest X-ray were
examined at 12 months of treatment.
Statistical analysis
Data were analyzed according to randomized treatment assignments
of participants regardless of their subsequent medication status
(intention-to-treat analysis) and expressed as the mean7s.d. The
mean values in the two groups were compared by unpaired t-test.
Analysis of variance with repeated measurements and subsequent
multiple comparison test (Dunnett) were applied to test the effect of
treatment on BPs, heart rate, and urinary protein/Cr ratio. We
compared the occurrence of cardiovascular events and death
between the two groups using w2 test. Statistical significance was
set at Po0.05.
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